Suppliers and packagers for generic pharmaceutical drug: voclosporin

voclosporin

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Aurinia	LUPKYNIS	voclosporin	CAPSULE;ORAL	213716	NDA	Aurinia Pharma U.S., Inc.	75626-001-02	3 PACKET in 1 CARTON (75626-001-02) / 4 BLISTER PACK in 1 PACKET (75626-001-01) / 15 CAPSULE in 1 BLISTER PACK	2021-01-22

Voclosporin Suppliers: Contract Manufacturing and Key Upstream Capabilities

Last updated: April 26, 2026

Who supplies voclosporin drug substance (API) and finished product?

Voclosporin is supplied through a mix of branded and generic commercial sources, with production typically split into (1) API manufacturing and (2) sterile/controlled finished-dose manufacturing when in capsule or other dosage forms. Commercial market access for voclosporin (Lupkynis) is driven by the originator supply chain plus contracted manufacturing for global distribution, while generic market entries rely on licensed API and finished-dose manufacturers.

What follows is the supplier landscape in terms of typical roles in the supply chain for voclosporin (API, drug product, and bridging services like analytical development and stability testing). Without a specific market (US/EU/ROW), pack size, strength, or application (commercial vs clinical), the supplier list cannot be pinned to a single set of named entities with full confidence.

Which companies are in the voclosporin supply chain?

Publicly disclosed supplier identities for voclosporin vary by jurisdiction and dosage form, and they change as contracts rotate. The originator finished product (Lupkynis) is distributed by the brand owner’s commercial organization, while API and drug product manufacturing can be performed by contract partners in the US and EU depending on regulatory approvals and manufacturing ownership changes.

At a practical level, due diligence for voclosporin supplier qualification is usually structured into three workstreams:

• API source qualification (DMF/CEP-backed)
• Drug product manufacturing qualification (sterile/solid-state controls as applicable)
• Quality systems alignment (GMP, control strategy, stability, shipping and storage)

What supplier types matter for voclosporin procurement?

API manufacturers (voclosporin bulk drug substance)

• Provide drug substance under cGMP
• Support regulatory filing references (DMF in the US; CEP in the EU when used)
• Supply CoA, impurity profile, and stability data per change-control category

Drug product manufacturers

• Produce the dosage form used for commercial supply (including packaging and labeling)
• Maintain validated processes and full traceability for batch release
• Support comparative assessments for any post-approval change (site transfer, process change, or specification update)

Secondary services

• Analytical testing and stability programs
• Reference standards and impurity characterization
• Scale-up support for clinical-to-commercial tech transfer

How do companies qualify as reliable voclosporin suppliers?

For voclosporin specifically, buyers should require proof across the following screens:

Regulatory package completeness

• DMF/CEP alignment to the buyer’s target market
• Impurity specification coverage (including known and potential related substances)
• Method capability to reproduce key assays under cGMP conditions

Quality systems

• GMP inspection history with no critical findings affecting sterility/assay controls (as applicable to dosage form)
• Data integrity controls and deviation/CAPA discipline

Supply assurance

• Batch release lead times and safety-stock policy
• Capacity for multi-strength commercialization (if portfolio requires)

Change control governance

• Clear process for site transfer, scale-up, and revalidation triggers
• Documented comparability outcomes under established regulatory pathways

What is the typical supplier selection approach for voclosporin?

A buyer typically runs a two-step qualification path:

1. Regulatory-alignment screen

   • Confirms the supplier can support the target market filing route
   • Ensures the impurity and assay package matches the buyer’s spec expectations

2. Commercial qualification

   • Audits the manufacturing site(s)
   • Conducts sample testing (assay, impurities, polymorph/crystal form controls if applicable)
   • Locks the supply agreement with batch schedule and change-control terms

What terms should buyers put into voclosporin supplier agreements?

Given voclosporin’s high-value specialty status and tight quality controls, agreements should lock:

• Lot release responsibilities
• Testing method ownership and dispute resolution
• Stability data update cadence
• Deviation and OOS notification timelines
• Change-control advance notice windows
• Audit rights and regulatory inspection cooperation

Key Takeaways

• Voclosporin sourcing is structured around API manufacturing and drug product manufacturing, with qualification driven by filing alignment (DMF/CEP) and impurity/spec control.
• Reliable suppliers are those that can demonstrate complete regulatory documentation, repeatable quality performance, and supply continuity across batch release and stability obligations.
• Supplier qualification for voclosporin is typically executed through regulatory alignment screening and commercial qualification (audit plus sample testing), then formalized through tight change-control and release terms.

FAQs

1) What is the difference between voclosporin API suppliers and drug product suppliers?

API suppliers provide bulk voclosporin with regulatory chemistry and impurity documentation. Drug product suppliers manufacture the finished dosage form and manage packaging, labeling, and release testing at the product level.

2) Do voclosporin API suppliers need DMF or CEP support?

For most regulated markets, buyers typically require filing-support documentation such as a US DMF or an EU CEP or equivalent regulatory reference aligned to the intended submission and market.

3) How should voclosporin stability data be handled during qualification?

Buyers normally require a stability package covering the intended shelf life and storage conditions, plus a plan for ongoing updates during commercial supply, including how changes will trigger protocol updates.

4) What quality attributes matter most for voclosporin?

Assay potency and a robust related-substances/impurity profile are core. Additional controls depend on the dosage form and manufacturing process, including validated test methods and batch release data integrity.

5) What supply risks are most common with niche specialty APIs like voclosporin?

The most common risks are constraints in batch release timing, limited second-source coverage, and delayed change-control documentation when manufacturing sites or processes are updated.

---

References

[1] FDA. “Lupkynis (voclosporin) prescribing information.” U.S. Food and Drug Administration.
[2] European Medicines Agency (EMA). “Lupkynis EPAR: Product information and assessment documents for voclosporin.” EMA.